Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan


Multi Drug Resistance, Tuberculosis, DOT, Lahore, M. tuberculosis.

How to Cite

Sana Saeed, Moosa Raza, Maryam Shabbir, Muhammad Furqan Akhtar, Ali Sharif, Muhammad Zaman, Sajid Ali, Sajid Nawaz, & Ayesha Saeed. (2018). Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan. Journal of Basic & Applied Sciences, 14, 107–112.


Purpose: The present prospective cross sectional study was aimed to access the prevalence and trend of Multi-Drug Resistant Tuberculosis (MDR-TB) in different age groups and gender, in the city of Lahore, Pakistan. Tuberculosis is a disease of poverty affecting mostly young adults in their most productive years; however, all age groups are at risk.
Method: The study population consisted of patients under DOT program with MDR-TB among males and females and in different categories of age groups. The data was collected from 100 MDR-TB patients from 7800 TB patients that were admitted in duration of 6 months and analyzed to evaluate the drug resistance associated with patient’s noncompliance. Moreover, drugs resistance ratio was also calculated from the data.
Results: TB is a specific infectious disease, caused by M. tuberculosis strains, which is becoming resistant to anti-tuberculosis agents especially to Isoniazid and Rifampicin that are two key drugs of TB treatment and are termed as MDR-TB. The disease was seen in 66% males and 34% in female. The highest drug resistance ratio was in found in adults (age group).


Organization WHO. Global tuberculosis report 2013: World Health Organization; 2013.

McPhee SJ, Papadakis MA, Rabow MW, Education M-H. Current medical diagnosis & treatment 2010: McGraw-Hill Medical; 2010.

Organization WHO. Global tuberculosis control: WHO report 2010: World Health Organization; 2010.

Wood AJ, Iseman MD. Treatment of multidrug-resistant tuberculosis. New England Journal of Medicine 1993; 329(11): 784-91.

Dye C, Bassili A, Bierrenbach A, Broekmans J, Chadha V, Glaziou P, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. The Lancet infectious diseases 2008; 8(4): 233-43.

Tanveer M, Hasan Z, Siddiqui AR, Ali A, Kanji A, Ghebremicheal S, et al. Genotyping and drug resistance patterns of M. tuberculosis strains in Pakistan. BMC infectious diseases 2008; 8(1): 171.

Organization WHO. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009: World Health Organization; 2009.

Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4(9): e6914.

Shehzadi R, Irfan M, Zohra T, Khan JA, Hussain SF. Knowledge regarding management of tuberculosis among general practitioners in northern areas of Pakistan. Journal-Pakistan Medical Association 2005; 55(4): 174.

Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bulletin of the World health Organization 2008; 86(3): B-D.

Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM, et al. Prevalence and risk factors for multidrug-resistant Tuberculosis in Republic of Georgia: a population based study. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 2009; 13(1): 68.

Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS medicine 2011; 8(7): e1001067.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2018 Journal of Basic & Applied Sciences